Saslow, D., Solomon, D., Lawson, H.W., et al. (2012) American Cancer Society, American Society for Colposcopyand Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the Prevention and Early Detection of Cervical Cancer. American Journal of Clinical Pathology, 137, 516-542. http://dx.doi.org/10.1309/AJCPTGD94EVRSJCG

has been cited by the following article:

• TITLE: Evaluation of HPV Molecular Tests in Primary Screening for Cervical Cancer in Brazil

  AUTHORS: José E. Levi, Adhemar Longatto-Filho, José Eluf-Neto, Célia L. Rodrigues, Cristina M. Oliveira, Adriana C. Carloni, Adriana T. Lorenzi, Maricy Tacla, José H. Fregnani, Alexandre M. Ab’Saber, Cristovam Scapulatempo, Luisa L. Villa

  KEYWORDS: High-Risk HPV Test, HPV-DNA, Cervical Cancer Screening

  JOURNAL NAME: Open Journal of Obstetrics and Gynecology, Vol.4 No.8, June 12, 2014

  ABSTRACT: Background: Incorporation of HPV tests into cervical cancer screening programs may be advantageous over conventional cytology, especially in developing nations, where the largest burden of cervical cancer is observed. Objectives: To conduct an evaluation of commercially available molecular HPV tests in Brazilian women. Study design: Two groups were recruited: group A was composed of 511 women referred to the clinics because of a previous abnormal Pap test while group B consisted of 2464 subjects under routine screening. Cervical samples were collected using SurePath liquid cytology (LBC) device, and split into aliquots which were submitted to molecular testing by Hybrid Capture and cobas HPV. Colposcopy and biopsies were made according to the standard guidelines, directed by cytological diagnosis. Results: Prevalence of HSIL was 5.97% and 0.7% in Group A and B respectively. High-Risk HPV DNA was found in about 9% of group B women, while in group A this frequency was 24%. Having CIN3+ as the study end-point, the negative predictive values for molecular methods were above 99.8%. All “in-situ” and invasive cervical carcinomas were detected by both HPV nucleic acid assays. Conclusion: Use of HPV DNA testing was feasible and highly sensitive in cancer screening settings of Brazil.